| Name | Title | Contact Details |
|---|
Community Health Partnership of Illinois (CHP) is a non-profit organization that provides high quality, patient centered healthcare to uninsured, underserved, migrants, seasonal agricultural workers and their families across rural and urban communities...
Rural Wisconsin Health Cooperative is a Sauk City, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases.
FORTE is a female founded and led technology company. Launched by Lauren Foundos in 2015, FORTË`s while label streaming platform helps boutique fitness studios, big box gyms and health clubs create premium live and on-demand fitness experiences for members. The FORTË solution is proprietary, turn-key and all inclusive. The company provides hardware and software, and facilitates the entire installation process. By removing complexities associated with production, FORTË`s fully-automated streaming solution allows fitness operators to focus on what they do best - create world-class content and deliver it to members wherever they are.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.